KOL Insight

This interview covers the current treatment of multiple myeloma in the UK, and the main areas of unmet need.

January 18, 2019

Datamonitor Healthcare Multiple Myeloma KOL Interview – Midwestern, US

This interview covers the current treatment of multiple myeloma in the US, and the main areas of unmet need.

January 18, 2019

Datamonitor Healthcare Meningococcal and Pneumococcal Vaccines KOL Interview – US

An interview with a US key opinion leader (KOL) on meningococcal and pneumococcal vaccination coverage rates, vaccination rate trends in main risk groups, key marketed vaccines, pipeline approaches, and addressing unmet needs.

November 9, 2018

Datamonitor Healthcare Meningococcal and Pneumococcal Vaccines KOL Interview – UK

An interview with a UK key opinion leader (KOL) on meningococcal and pneumococcal vaccination coverage rates, vaccination rate trends in main risk groups, key marketed vaccines, pipeline approaches, and addressing unmet needs.

November 12, 2018

Datamonitor Healthcare Major Depressive Disorder KOL Interview – US #2

A US key opinion leader (KOL) discusses the approach to treating major depressive disorder as well as the most pressing unmet needs in the market, and provides insights into key late-phase pipeline drugs for major depressive disorder.

October 2, 2018

Datamonitor Healthcare Major Depressive Disorder KOL Interview – US #1

A US key opinion leader (KOL) discusses key late-phase pipeline and marketed drugs for major depressive disorder and highlights the significance of unique mechanisms of action in the market.

October 2, 2018

Datamonitor Healthcare Infectious Diseases Disease Analysis: Seasonal Influenza Vaccines

The seasonal influenza vaccines market in the US, Japan, and five major European markets (France, Germany, Italy, Spain, and the UK) is expected to continue to expand over the next 10 years, largely due to the continued uptake of premium-priced vaccines in the elderly subgroup, including quadrivalent forms of Fluzone High-Dose (HD) and Fluad, as well as the launch of the first-in-class adjuvanted nanoparticle vaccine, NanoFlu.

October 30, 2020

Datamonitor Healthcare HR+/HER2- Breast Cancer KOL Interview – US, West Coast

A US key opinion leader (KOL) provides insight into the current and future treatment dynamics of HR+/HER2- breast cancer, as well as critical unmet needs in the treatment space.

January 8, 2019

Datamonitor Healthcare HR+/HER2- Breast Cancer KOL Interview – US, Midwest

A US key opinion leader (KOL) provides insight into the current and future treatment dynamics of HR+/HER2- breast cancer, as well as critical unmet needs in the treatment space.

January 8, 2019

Datamonitor Healthcare HR+/HER2- Breast Cancer KOL Interview – UK

A UK key opinion leader (KOL) provides insight into the current and future treatment dynamics of HR+/HER2- breast cancer, as well as critical unmet needs in the treatment space.

January 8, 2019

Datamonitor Healthcare HIV KOL Interview – US #2

A US key opinion leader (KOL) provides insights into the HIV treatment market, including a discussion on prescribing trends, key marketed therapies, impact of generic launches, and pipeline therapies.

Datamonitor Healthcare HIV KOL Interview – US #1

A US key opinion leader (KOL) provides insights into the HIV treatment market, including a discussion on prescribing trends, key marketed therapies, impact of generic launches, and pipeline therapies.

Datamonitor Healthcare HIV KOL Interview – UK

A UK key opinion leader (KOL) provides insights into the HIV treatment market, including a discussion on prescribing trends, key marketed therapies, impact of generic launches, and pipeline therapies.

Datamonitor Healthcare HIV KOL Interview – Germany

A German key opinion leader (KOL) provides insights into the HIV treatment market, including a discussion on prescribing trends, key marketed therapies, impact of generic launches, and pipeline therapies.

Datamonitor Healthcare Hepatocellular Carcinoma (HCC) KOL Interview – US, South #2

This interview provides a thorough description of hepatocellular carcinoma (HCC) treatment in the US. All targeted therapies available for HCC treatment are discussed, as well as a discussion of Phase III pipeline drugs and the potential impact these therapies would have if they gain approval.

February 6, 2019